Artiva Biotherapeutics vs ImageneBio
ARTV and IMA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARTV and IMA compare
Artiva Biotherapeutics is the larger company, worth 4.7 times as much as ImageneBio ($199M against $42.2M).
Artiva Biotherapeutics scores higher on the StockData Score (8 against 7 for ImageneBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARTV | IMA |
|---|---|---|
| Size and price | ||
| Market cap | $199M | $42.2M |
| Share price | $4.07 | $3.72 |
| Change, 1 year | 11.2% | −54.6% |
| Change, 5 years | – | −98.0% |
| Beta (5Y) | 2.32 | 1.18 |
| Employees | 104 | 15 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× | 0.3× (better) |
| FCF yield | −43.5% | – |
| Growth | ||
| Revenue growth, 5Y average | – | −38.6% |
| Profitability | ||
| Return on equity | −43.6% | −32.3% (better) |
| Return on invested capital | −2120% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 19.88 (better) | 16.17 |
| Altman Z-score | 3.77 (better) | −0.99 |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 83.2% | 54.9% |
| Held by insiders | 68.3% | 52.9% |
| Insider net buying, 12 months | $106M (better) | $78.5K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 19.0% | 0.86% |
Go deeper
- ARTV stock overview
- ARTV income statement
- ARTV valuation and score
- IMA stock overview
- IMA income statement
- IMA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.